Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
The primary objective is to confirm the efficacy of intravaginal prasterone (DHEA) on Hypoactive Sexual Desire Disorder (HSDD) in postmenopausal women.
Epistemonikos ID: a97967e8f053017c08d9af936ac375d675729f78
First added on: May 21, 2024